Calithera Biosciences Inc. said the phase 1 study of CB-839, in combination with paclitaxel, showed responses in heavily pretreated patients with advanced/metastatic triple negative breast cancer, or TNBC.
Calithera said data from the trial exhibited tolerability of CB-839 and highlighted the "unique mechanism of action" of the therapy.
The combination treatment has been well-tolerated, with side effects that are primarily low-grade and reversible, including neutropenia — a blood condition wherein the level of a certain type of white blood cell drops.
Calithera has opened a phase 2 trial to further evaluate the combo in both first-line and late-line metastatic TNBC.
